Our Work
Digital health intelligence applied to consequential decisions
See how healthcare, life sciences, investment, and innovation teams use Galen Growth to move from broad market questions to evidence-backed action.
Use cases
Start with the decision
Market expansion
Prioritise geographies, categories, and partners using comparable ecosystem evidence.
Explore capability →02Market access intelligence
Understand adoption pathways, evidence expectations, and routes into healthcare markets.
Explore capability →03Health innovation strategy
Turn market signals into focused roadmaps and clear build, buy, or partner decisions.
Explore capability →04Competitive intelligence
Track how peers invest, partner, launch, and reposition across digital health.
Explore capability →05Portfolio evaluation and risk
Compare portfolio companies and partnerships consistently to identify material risk.
Explore capability →06Due diligence
Test market claims, traction, evidence, partnerships, and execution risk before committing resources.
Explore capability →07Ecosystem mapping
Map the ventures, relationships, and signals shaping a defined digital health landscape.
Explore capability →08Startup and partner scouting
Find and prioritise ventures matched to a specific healthcare need and evidence threshold.
Explore capability →Selected engagements
How Galen Growth has helped
Benchmarking Singapore’s Digital Health Ecosystem Against Global Peers
How does Singapore’s Digital Health ecosystem compare globally, and where should national policy and investment focus?
Building a Startup Bridge in APAC for HPV, Cervical Cancer and Immuno-Oncology
Which APAC Digital Health ventures can help us drive HPV awareness, cervical cancer action and immuno-oncology innovation?
Mapping the Real-World Evidence Landscape in China for an Investor Thesis
Is real-world evidence in China a defensible thesis, and which ventures are emerging as category leaders?
Pressure-Testing an Existing Digital Health Portfolio for Fitness to Scale
Is our existing Digital Health portfolio fit for purpose against our updated franchise strategy?
Selecting Personal Health Ventures for Two Priority Therapeutic Areas
Which personal-health ventures are the optimal fit for our two priority therapeutic areas across the major global ecosystems?
Decoding the Pan-Omics Venture Landscape Across Europe and Asia
Where is pan-omics innovation concentrated across Europe and Asia, and which ventures warrant deeper engagement?
Shortlisting GDPR-Ready Telemonitoring Ventures for Heart Failure
Which telemonitoring ventures can credibly connect heart-failure patients with cardiologists and meet our eight enterprise criteria?
Identifying Ventures With Proven Digital Biomarker Scoring Capability
Which ventures have a proven, differentiated digital biomarker scoring algorithm in oncology?
Mapping Competitor Moves to Set a Differentiated APAC Strategy
Where are our regional competitors investing in Digital Health, and should we follow or differentiate?
Helping an APAC Insurer Prioritise Markets, Categories and Venture Targets
Which APAC markets, therapeutic areas and Digital Health categories should we prioritise to accelerate regional growth?
Pressure-Testing a Digital Health Partnership Before Commitment
How does our preferred venture partner compare against credible alternatives in the same market and therapeutic focus?
Sourcing HealthTech Ventures to Power Non-Fluid Underwriting
Which ventures across digital biomarkers, DTx, genomics and teleconsultation are mature enough to enable non-fluid underwriting?
Your decision context
Bring us the strategic question.
We will help define the evidence, scope, and path to a defensible answer.